GRISEOFULVIN

 Griseofulvin is fungistatic in vitro, and has a

narrow spectrum of antimycotic activity

 Not effective for candidiasis, deep fungal

infections, or pityriasis versicolor.
 GRISEOFULVIN
Mechanism Of Action
 Has a narrow antimycotic
 It disrupts microtubule mitotic spindle
formation.
 GRISEOFULVIN
Pediatric
Griseofulvin is recommended at a dosage higher
than that suggested
- 20–25 mg/kg/day (microsize) or
- 15–20 mg/kg/day (ultramicrosize) to complete
a minimum course of 6–8 weeks for T.
tonsurans.
- Longer treatment with griseofulvin is
recommended for M. canis infections
The first-line treatment of tinea capitis in children
 GRISEOFULVIN
Adult

 Griseofulvin is indicated for the treatment of

fingernail and toenail onychomycosis

 Requiring approximately 6 months for the

treatment of fingernails and 12 months for
toenails
Therapy is prolonged with low cure and high relapse rates
Geriatric

The safety of griseofulvin therapy in the elderly

has not been formally evaluated in trials
 GRISEOFULVIN
Pregnancy Consi derations

 Griseofulvin is a pregnancy category C drug

 Griseofulvin interferes with chromosomal

distribution during cell division

 Males should wait at least 6 months after

completing griseofulvin therapy before fathering a
child
GRISEOFULVIN